Accession |
PRJCA002282 |
Title |
Circulating tumor DNA is capable of monitoring the therapeutic response and resistance in advanced colorectal cancer patients undergoing combined target and chemotherapy |
Relevance |
Medical |
Data types |
Raw sequence reads
Genome sequencing
|
Organisms |
Homo sapiens
|
Description |
Colorectal cancer (CRC) is a highly lethal disease worldwide. The majority of patients receiving targeted therapy or chemotherapy develop drug resistance, while its molecular mechanism remains to be elucidated. The plasma circulating tumor DNA (ctDNA) exhibited the potential in identifying gene variations and monitoring drug resistance in CRC treatment. In this study, we monitored the ctDNA mutational changes in advanced CRC patients underwent first-line therapy with bevacizumab and cetuximab combined with chemotherapy. The dynamic change of plasma mutation status was consistent with the tissue tumor burden and was closely correlated with disease progression. In conclusion, ctDNA monitoring is a useful method for molecular genotyping of colorectal cancer patients. Dynamic changes in resistance can be sensitively monitored by gene variation status, which potentially helps to develop treatment strategy. |
Sample scope |
Multiisolate |
Release date |
2020-02-26 |
Grants |
Agency |
program |
Grant ID |
Grant title |
Sanming project of Shenzhen People Hospital
|
|
SYLY201725
|
|
|
Submitter |
lele
song (songlele@sina.com)
|
Organization |
HaploX Biotechnology Co., Ltd |
Submission date |
2020-02-26 |